MX344222B - Una formulacion novedosa de naproxeno. - Google Patents

Una formulacion novedosa de naproxeno.

Info

Publication number
MX344222B
MX344222B MX2011011220A MX2011011220A MX344222B MX 344222 B MX344222 B MX 344222B MX 2011011220 A MX2011011220 A MX 2011011220A MX 2011011220 A MX2011011220 A MX 2011011220A MX 344222 B MX344222 B MX 344222B
Authority
MX
Mexico
Prior art keywords
naproxen
novel formulation
compositions
particles
methods
Prior art date
Application number
MX2011011220A
Other languages
English (en)
Spanish (es)
Other versions
MX2011011220A (es
Inventor
Norret Marck
Dodd Aaron
Meiser Felix
Russell Adrian
H Bosch William
Original Assignee
Iceutica Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009901746A external-priority patent/AU2009901746A0/en
Application filed by Iceutica Pty Ltd filed Critical Iceutica Pty Ltd
Publication of MX2011011220A publication Critical patent/MX2011011220A/es
Publication of MX344222B publication Critical patent/MX344222B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2011011220A 2009-04-24 2010-04-23 Una formulacion novedosa de naproxeno. MX344222B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17228909P 2009-04-24 2009-04-24
AU2009901746A AU2009901746A0 (en) 2009-04-24 A Novel Formulation of Naproxen
PCT/AU2010/000470 WO2010121326A1 (en) 2009-04-24 2010-04-23 A novel formulation of naproxen

Publications (2)

Publication Number Publication Date
MX2011011220A MX2011011220A (es) 2012-02-08
MX344222B true MX344222B (es) 2016-12-07

Family

ID=43010609

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011220A MX344222B (es) 2009-04-24 2010-04-23 Una formulacion novedosa de naproxeno.

Country Status (19)

Country Link
US (5) US20120148634A1 (https=)
EP (1) EP2421512A4 (https=)
JP (2) JP6116244B2 (https=)
KR (3) KR20160135370A (https=)
CN (2) CN103877030A (https=)
AP (1) AP3530A (https=)
AU (1) AU2010239085C1 (https=)
CA (1) CA2759122A1 (https=)
CO (1) CO6470806A2 (https=)
EA (1) EA201171284A1 (https=)
IL (1) IL215868A0 (https=)
MA (1) MA33299B1 (https=)
MX (1) MX344222B (https=)
NZ (2) NZ595985A (https=)
SG (2) SG175767A1 (https=)
TN (1) TN2011000536A1 (https=)
UA (1) UA111578C2 (https=)
WO (1) WO2010121326A1 (https=)
ZA (1) ZA201108648B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007264418B2 (en) 2006-06-30 2012-05-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
SG10201607849TA (en) * 2009-04-24 2016-11-29 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
CN102438594A (zh) 2009-04-24 2012-05-02 伊休蒂卡有限公司 吲哚美辛的新剂型
KR101794032B1 (ko) * 2011-09-21 2017-11-07 (주)바이오시네틱스 나노입자 제조방법
WO2015179098A1 (en) 2014-05-21 2015-11-26 Integenx Inc. Fluidic cartridge with valve mechanism
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US11175268B2 (en) 2014-06-09 2021-11-16 Biometry Inc. Mini point of care gas chromatographic test strip and method to measure analytes
CN106537128B (zh) 2014-06-09 2021-06-18 生物统计股份有限公司 用于测量分析物的低成本测试条和方法
GB201506755D0 (en) 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
CN107106983B (zh) 2014-10-22 2021-04-16 尹特根埃克斯有限公司 用于样品制备、处理和分析的系统和方法
US10210410B2 (en) 2014-10-22 2019-02-19 Integenx Inc. Systems and methods for biometric data collections
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
WO2017136617A1 (en) 2016-02-04 2017-08-10 Cinrx Pharma, Llc Deuterated domperidone compositions and methods for therapy of disorders
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
CN114859028A (zh) 2016-07-19 2022-08-05 生物统计股份有限公司 使用批量可校准测试条测量分析物的方法和系统
JP7163015B2 (ja) * 2016-10-31 2022-10-31 エスエス製薬株式会社 経口固形組成物
AU2018255063A1 (en) * 2017-04-21 2018-11-22 Bio-Synectics Inc. Method for preparing active material nanoparticles using lipid as lubricant for milling
US12478612B2 (en) 2017-06-30 2025-11-25 Cindome Pharma, Inc. Deuterated domperidone compositions, methods, and preparation
US11779541B2 (en) 2019-03-26 2023-10-10 Johnson & Johnson Consumer Inc. Immediate release dosage form
DK4245298T3 (en) * 2020-12-18 2026-03-30 Daewoong Pharmaceutical Co Ltd Hidtil ukendt formulering til oral administration, som omfatter 1-(5-(2,4-difluorphenyl)-1-((3-fluorphenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamin
KR20250112022A (ko) * 2024-01-16 2025-07-23 피투케이바이오 주식회사 리바록사반 흡입용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
DE60203506T2 (de) * 2001-06-22 2006-02-16 Marie Lindner Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics
EP1830824B1 (en) * 2004-12-31 2016-01-13 Iceutica Pty Ltd. Nanoparticle composition and methods for synthesis thereof
AU2007264418B2 (en) * 2006-06-30 2012-05-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
KR20090027734A (ko) * 2006-07-27 2009-03-17 (주)아모레퍼시픽 난용성 약물의 나노입자를 포함하는 분말의 제조방법
AP3138A (en) * 2009-04-24 2015-02-28 Iceutica Pty Ltd Production of encapsulated nanoparticles at high volume fractions
JP5898613B2 (ja) * 2009-04-24 2016-04-06 イシューティカ ピーティーワイ リミテッド 生物学的活性物質の溶解プロファイルを改善するための方法
US20120160944A1 (en) * 2009-04-24 2012-06-28 Aaron Dodd Method for the production of commercial nanoparticle and micro particle powders
SG10201607849TA (en) * 2009-04-24 2016-11-29 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale

Also Published As

Publication number Publication date
WO2010121326A1 (en) 2010-10-28
EP2421512A4 (en) 2013-01-23
US20150087709A1 (en) 2015-03-26
NZ626401A (en) 2015-12-24
KR20160135370A (ko) 2016-11-25
JP6177275B2 (ja) 2017-08-09
UA111578C2 (uk) 2016-05-25
US20150313857A1 (en) 2015-11-05
CO6470806A2 (es) 2012-06-29
US20160220518A1 (en) 2016-08-04
CA2759122A1 (en) 2010-10-28
MA33299B1 (fr) 2012-05-02
CN102438592A (zh) 2012-05-02
AU2010239085A1 (en) 2011-11-10
MX2011011220A (es) 2012-02-08
IL215868A0 (en) 2012-01-31
EP2421512A1 (en) 2012-02-29
US20140200276A1 (en) 2014-07-17
TN2011000536A1 (en) 2013-05-24
CN102438592B (zh) 2016-09-14
JP2015166379A (ja) 2015-09-24
KR20120104489A (ko) 2012-09-21
AP3530A (en) 2016-01-13
ZA201108648B (en) 2013-01-30
JP6116244B2 (ja) 2017-04-19
CN103877030A (zh) 2014-06-25
SG10201401720RA (en) 2014-06-27
AU2010239085C1 (en) 2014-10-16
US20120148634A1 (en) 2012-06-14
KR20150008909A (ko) 2015-01-23
JP2012524722A (ja) 2012-10-18
EA201171284A1 (ru) 2012-05-30
SG175767A1 (en) 2011-12-29
AP2011005991A0 (en) 2011-12-31
AU2010239085B2 (en) 2014-07-03
NZ595985A (en) 2014-07-25

Similar Documents

Publication Publication Date Title
MX344222B (es) Una formulacion novedosa de naproxeno.
CO6470810A2 (es) Una formulación novedosa de diclofenaco
CO6470807A2 (es) Una formulacion novedosa de indometacina
CO6470803A2 (es) Una formulacion novedosa de meloxicam
MX2011011218A (es) Produccion de nanoparticulas encapsuladas a escala comercial.
CO6470805A2 (es) Producción de monopartículas encapsuladas en fracciones de alto volumen
UY35210A (es) Inhibidores de autotaxina
MX364102B (es) Medicamentos para usarse en el tratamiento de la encefalopatía hepática.
CO6470812A2 (es) Método para la producción de polvos de nanopartículas y micropartículas comerciales
CR20110485A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
SV2011003855A (es) Heteroarilos sustituidos
HN2010002518A (es) Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina
DOP2009000287A (es) Oxazolidinonas sustituidas y su uso
MX2011011233A (es) Una formulacion novedosa de metaxalona.
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
DOP2009000285A (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulacion sanguinea.
ECSP14027694A (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
BR112014030992A2 (pt) composições compreendendo calcogenetos e métodos relacionados
BRPI1015538A2 (pt) nova formulação de naproxeno
AU2014208310B2 (en) A Novel Formulation of Diclofenac

Legal Events

Date Code Title Description
FG Grant or registration